Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Steris

Steris Reaches 80-Plus Relative Strength Rating Benchmark

Steris sees its Relative Strength Rating reach the 80-plus level.

Investors Business Daily

Stocks Generating Improved Relative Strength: Steris

Steris shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?

Medical stocks could see a resurgence if the economy hits a speed bump due to tariffs. But which health care stocks are worth watching?

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Flashing Renewed Technical Strength: Steris

A Relative Strength Rating upgrade for Steris shows improving technical performance.

Investors Business Daily

Steris Earns Relative Strength Rating Upgrade; Hits Key Threshold

Steris sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

Stocks With Rising Relative Strength: Steris

A Relative Strength Rating upgrade for Steris shows improving technical performance. Will it continue?

Investors Business Daily

Is STERIS Stock Underperforming the Dow?

Despite STERIS’ underperformance relative to Dow Jones over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Steris Stock Gets Relative Strength Rating Lift

A Relative Strength Rating upgrade for Steris shows improving technical performance. Will it continue?

Investors Business Daily

Steris Stock Gets Relative Strength Rating Lift

A Relative Strength Rating upgrade for Steris shows improving technical performance. Will it continue?

Investors Business Daily

Here's What to Expect from STERIS’ Next Earnings Report

Healthcare major STERIS is expected to announce its third-quarter earnings in the upcoming month and analysts expect a modest single-digit growth in earnings.

Barchart

Is STERIS Stock Underperforming the Nasdaq?

STERIS stock has significantly underperformed the Nasdaq over the past 52 weeks, yet analysts remain strongly bullish on the stock’s prospects.

Barchart

Is STERIS Stock Underperforming the S&P 500?

STERIS has underperformed the S&P 500 over the past year, yet analysts remain moderately bullish about the stock’s potential.

Barchart

3 Healthcare Innovators Transforming Patient Care

The healthcare industry's long-term growth is fueled by rising R&D initiatives and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid medical device stocks Alcon (ALC), Becton, Dickinson and Company (BDX), and STERIS (STE) for potential returns. Keep reading.

StockNews.com

STERIS Stock Outlook: Is Wall Street Bullish or Bearish?

STERIS has underperformed the broader market over the past year, yet analysts remain moderately bullish on the stock’s potential.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2022

Upgrades

Bangkok Post

Please join “Business and Investment Opportunities in the Medical Sector in Thailand”

Thailand Board of Investment (BOI), Paris Office, cordially invites companies to join its webinar on Business and Investment Opportunities in the Medical Sector in Thailand with BOI Headquarters, Bangkok Dusit Medical Service (BDMS), Thai Food and Drug Administration (FDA), Sanet Asean Advisors, and STERIS (AST)

Benzinga

Ominous Death Cross Forms On Steris's Chart

If history is any guide, there may be trouble ahead for shares of Steris (NYSE:STE). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

Steris: Q4 Earnings Insights

Steris (NYSE:STE) reported its Q4 earnings results on Wednesday, May 11, 2022 at 04:30 PM. Here's what investors need to know about the announcement. Earnings Steris beat estimated earnings by 0.99%, reporting an EPS of $2.04 versus an estimate of $2.02.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

UnitedHealth, Vertex Lead Five Stocks Looking Healthy In A Weak Market

UnitedHealth and Vertex Pharmaceuticals are among five medical stocks with healthy action in a weak market.

Investors Business Daily

This Screen IDs Hot Stocks To Watch: Costamere, Ares, Steris Shine

The Rising Profits Estimates screen reveals hot stocks to watch, such as Costamare, Ares Management and Steris.

Benzinga

Steris Q3 Sales Jump 50% To $1.2B, Revises FY22 Guidance

Steris plc (NYSE: STE)

Benzinga

Recap: Steris Q3 Earnings

Steris (NYSE:STE) reported its Q3 earnings results on Tuesday, February 8, 2022 at 04:30 PM. Here's what investors need to know about the announcement. Earnings Steris beat estimated earnings by 7.61%, reporting an EPS of $2.12 versus an estimate of $1.97.

People

David Wagner

69 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Vertex Pharmaceuticals

Apollo Global Management

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.